Oregon Makes History as First State to Legalize Medical Ibogaine — What This Means for Addiction Treatment Access

On February 12, 2026, Oregon passed House Bill 4110, making history as the first state in the United States to legalize physician-supervised ibogaine treatment. This bipartisan legislation, championed by Republican Representative Alek Skarlatos and Democratic sponsors, represents a seismic shift in how America approaches addiction treatment. But what does this mean for people struggling with opioid addiction, alcoholism, and PTSD?

And why did Oregon move first where the federal government has dragged its feet for decades? The answer lies in desperation — and data. The Addiction Crisis Oregon Couldn't Ignore Oregon has been ground zero for America's addiction epidemic. In 2023, the state recorded over 1,200 drug overdose deaths, with fentanyl-related fatalities rising 183% since 2019.

Traditional treatment modalities — methadone, Suboxone, residential rehab — have shown modest success rates at best. The state's experiment with drug decriminalization (Measure 110) intended to redirect resources toward treatment, but without effective treatment options, the policy faltered. Enter ibogaine. For years, Oregon's legislators watched as constituents traveled to Mexico, Canada, and Central America seeking physician-supervised ibogaine treatment — a plant-derived alkaloid from the African Tabernanthe iboga shrub.

These patients returned with stories that seemed too good to be true: complete elimination of opioid cravings, resolution of withdrawal symptoms, and profound psychological insights that allowed them to address the root causes of their addiction. Skarlatos, a U. Army veteran who served in Afghanistan, understood firsthand the connection between trauma and addiction. His district includes high rates of veteran suicide and opioid deaths.

When constituents began sharing their ibogaine success stories, he listened. And when Stanford Medicine published breakthrough research showing ibogaine's efficacy for PTSD and traumatic brain injury, he acted. What HB 4110 Actually Does Oregon's HB 4110 is not a blanket legalization. It's a carefully structured medical framework: Physician Authorization Required : Only licensed physicians trained in psychedelic-assisted therapy can administer ibogaine.

Pre-Treatment Screening : Mandatory cardiac screening (EKG) to rule out QT interval prolongation, a known cardiac risk. Medical Supervision : Treatment must occur in licensed clinical settings with cardiac monitoring equipment. Post-Treatment Integration : Patients receive at least three follow-up integration therapy sessions. Data Collection : The Oregon Health Authority will track outcomes to build evidence for nationwide policy change.

The bill explicitly carves out ibogaine from Schedule I status within Oregon, reclassifying it as a medical treatment similar to ketamine or MDMA in clinical trials. This means that while ibogaine remains federally illegal (Schedule I under the DEA), Oregon physicians can now prescribe and administer it without fear of state prosecution. The first Oregon clinics are expected to open by late 2026, pending regulatory framework finalization. Why This Matters — And Why It Took So Long Ibogaine has been known to Western medicine since the 1960s, when Howard Lotsof, a heroin addict, discovered that a single ibogaine experience eliminated his withdrawal symptoms and cravings.

He spent the rest of his life advocating for research and access. But the DEA classified ibogaine as Schedule I in 1970, alongside LSD and heroin, declaring it had "no accepted medical use. " That classification was never based on safety data. It was political.

Since then, over 30 countries have either legalized or tolerated ibogaine treatment. Mexico, in particular, has become a hub for addiction treatment in Cozumel and other resort areas, where Americans travel for treatments unavailable at home.

And when Stanford Medicine published breakthrough research showing ibogaine's efficacy for PTSD and traumatic brain injury, he acted.

The clinical outcomes have been documented in peer-reviewed journals: A 2017 study in the Journal of Psychopharmacology found that a single ibogaine treatment reduced opioid withdrawal symptoms by 80% within 24 hours. Stanford Medicine's MISTIC trial (published 2023, with 12-month follow-up in 2025) showed sustained improvements in PTSD, depression, and cognitive function among Special Operations veterans. Observational studies from treatment centers worldwide report 50-70% abstinence rates at one year post-treatment — vastly higher than methadone or Suboxone maintenance programs. Oregon's legislators reviewed this evidence and asked a simple question: If ibogaine works, why are we forcing our residents to travel to Mexico to access it?

HB 4110 is their answer. The Bipartisan Coalition That Made It Happen One of the most remarkable aspects of Oregon's ibogaine legislation is its bipartisan support. In an era of intense political polarization, addiction has become a rare unifying issue. Skarlatos, a conservative Republican from southern Oregon, partnered with Portland Democrats who had championed drug policy reform.

Their shared constituents — veterans, parents who lost children to fentanyl, people who'd tried every rehab program and failed — demanded alternatives. The coalition built support by focusing on medical access , not drug legalization. They framed ibogaine as a legitimate pharmaceutical intervention, not a recreational drug. They emphasized physician oversight, cardiac safety protocols, and data collection.

They invited testimony from patients who had traveled to Mexico for treatment and returned sober after years of failed attempts. One particularly powerful testimony came from a mother whose son, a former Marine, had survived three overdoses and seven rehab stays. After a single ibogaine treatment at a Mexican clinic, he had been sober for 18 months. "My son isn't on Suboxone.

He's not white-knuckling it day by day," she told the committee. "He's free . And Oregon told him he had to leave the country to get that freedom. " By the time HB 4110 reached a vote, opposition had collapsed.

What This Means for Patients — And the Limitations For Oregon residents struggling with addiction, HB 4110 offers hope. But it's essential to understand the limitations: Wait Times Will Be Long : Oregon's program will start with a limited number of trained physicians and licensed clinics. Early estimates suggest 6-12 month waitlists. Insurance Coverage Uncertain : Most private insurers do not yet cover ibogaine treatment.

Oregon's Medicaid program is still determining reimbursement policies. Not for Everyone : Cardiac contraindications (certain heart conditions), concurrent use of SSRIs, and other medical factors may disqualify some patients. Integration Is Critical : Ibogaine is not a magic bullet. Without proper integration therapy and lifestyle changes, relapse remains possible.

For patients who cannot wait — or who do not meet Oregon's criteria — what to expect during ibogaine treatment at established international clinics remains an option. Mexico's treatment centers, many of which have been operating safely for over a decade, continue to offer immediate access without waitlists. MindScape Retreat: A Decade Ahead of Oregon's Model At MindScape Retreat in Cozumel, we have been providing physician-supervised ibogaine treatment since 2015. Our protocols align closely with what Oregon's HB 4110 mandates: Medical Director Oversight : Dr.

Omar Calderon, M. , a board-certified addiction specialist, personally oversees every treatment. Pre-Treatment Cardiac Screening : We conduct comprehensive EKGs, bloodwork, and medical history reviews to rule out contraindications. 24/7 Monitoring : Patients are monitored by medical staff throughout the ibogaine experience, with cardiac equipment on-site.

TA + Hydrochloride Booster Protocol : We use a proprietary combination of total alkaloid (TA) and hydrochloride (HCL) ibogaine for deeper therapeutic effect — a protocol unavailable at most clinics. SSRI Specialization : Unlike many providers, we have successfully treated patients on SSRIs, a demographic often excluded from ibogaine protocols. Post-Treatment Integration : We provide aftercare planning and connect patients with integration therapists. Our outcomes mirror the research: over 200 patients treated, with sustained abstinence rates above 60% at one year.

Many of our patients have traveled from Oregon specifically because they couldn't access this treatment at home. Now, with HB 4110 passed, Oregon is catching up. But for patients who need treatment now — not in 6-12 months — MindScape remains a proven, accessible option.

The Ripple Effect: Will Other States Follow

Oregon's move is unlikely to be the last. Several states are watching closely: Texas has already allocated $50 million for ibogaine clinical trials at UTHealth Houston and UTMB. While not yet legalized for clinical use, the trials lay groundwork for future legislation. California has active psychedelic reform advocacy groups pushing for broader access to ibogaine and other plant medicines.

Colorado , which legalized psilocybin therapy in 2022, is considering adding ibogaine to its approved psychedelic treatment menu. Florida legislators have introduced preliminary bills exploring ibogaine for veteran PTSD, though progress has stalled. The pattern is clear: states are no longer waiting for federal permission. The DEA's Schedule I classification, once seen as insurmountable, is now viewed as obsolete by state lawmakers who have reviewed the clinical evidence.

Oregon's success — or failure — over the next 2-3 years will determine whether this becomes a nationwide movement or a regional experiment. What Patients Should Do Now If you or a loved one is struggling with opioid addiction, alcoholism, or PTSD, here's what Oregon's HB 4110 means for you: If you live in Oregon: Monitor the Oregon Health Authority's website for updates on licensed clinics and physician training programs. Begin researching integration therapists in your area. Post-ibogaine integration is essential for long-term success.

If you have cardiac conditions, consult a cardiologist about whether you'd be a candidate. If you can't wait for Oregon's program: Research established international clinics with strong safety records. Look for physician supervision, cardiac monitoring, and transparent protocols. Avoid underground providers or DIY ibogaine.

Cardiac risks are real, and medical supervision is non-negotiable. Budget for the full experience: treatment + travel + integration support. If you're in another state: Contact your state legislators and reference Oregon's HB 4110 as a model. Demand evidence-based addiction treatment options.

Share your story. Personal testimony from patients and families changes minds. A New Chapter in American Addiction Treatment For decades, America's addiction crisis has been met with punishment, stigma, and ineffective interventions. Oregon's HB 4110 represents a different path — one grounded in science, compassion, and respect for patient autonomy.

Ibogaine is not a panacea. It is a powerful tool that, when used responsibly under medical supervision, offers people a chance to break free from the neurochemical grip of addiction. The research supports it. The patient outcomes support it.

And now, for the first time, American law supports it. Oregon has opened the door. Other states will follow. And for the thousands of Americans who no longer have to choose between traveling abroad or dying of an overdose, this is a revolution.

At MindScape Retreat, we've seen this revolution unfold one patient at a time. We've watched people reclaim their lives, repair their families, and rediscover meaning after years of despair. Oregon's HB 4110 will bring that same transformation to American soil. The question is: How many more lives will be lost before the rest of the country follows Oregon's lead?